Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor

Atticus H. Hainsworth, Alessandro Stefani, Paolo Calabresi, Terence W. Smith, Michael J. Leach

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Sipatrigine is a substituted pyrimidine derived from lamotrigine. It attenuates glutamate release in vitro and in vivo, probably as a result of sodium and calcium channel inhibition. It consistently reduces cortical infarct volume in rodent models of global, permanent focal, and transient focal ischemia (typically 50-60% reduction with maximum effective doses >20 mg/kg). Striatal protection was found in some studies but not others. The drug was effective also in a rat optic nerve model of white matter ischemia, providing complete neuroprotection at the highest concentration (100 μM) used. In monkeys, CNS penetration by sipatrigine was rapid and the steady state brain/plasma ratio was >40. In humans, low doses (<2 mg/kg, then 1 mg/kg/8 h) were well tolerated. At higher doses a significant incidence of hallucinations and vomiting was observed. These adverse effects were speculated to be due to interactions with muscarinic receptors and 5-HT3 (or sigma) receptors, respectively. Cardiovascular side effects appeared not to be a major concern. In electrophysiological studies, sipatrigine inhibited native neuronal sodium and calcium channels (including L, N, and P/Q type) and recombinant type IIA sodium and N and T type calcium channels, all with similar potency (IC50 in the range 5-16 μM). Inhibitory potency was increased by high action potential firing frequencies and a depolarized resting voltage. These properties may account for its actions in vitro and in animal models but do not exclude possible additional actions in later stages of ischemic damage.

Original languageEnglish
Pages (from-to)111-134
Number of pages24
JournalCNS Drug Reviews
Volume6
Issue number2
Publication statusPublished - 2000

Fingerprint

Sodium Channels
Neuroprotective Agents
Calcium Channels
Ischemia
T-Type Calcium Channels
N-Type Calcium Channels
sigma Receptors
Corpus Striatum
Hallucinations
Muscarinic Receptors
Optic Nerve
Action Potentials
Inhibitory Concentration 50
Vomiting
Haplorhini
Glutamic Acid
Rodentia
Animal Models
Sodium
Incidence

Keywords

  • Brain injury
  • Cerebral ischaemia
  • Excitotoxicity
  • Glutamate release
  • Lamotrigine
  • Neuroprotection
  • Sipatrigine
  • Stroke

ASJC Scopus subject areas

  • Pharmacology
  • Neuropsychology and Physiological Psychology

Cite this

Hainsworth, A. H., Stefani, A., Calabresi, P., Smith, T. W., & Leach, M. J. (2000). Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. CNS Drug Reviews, 6(2), 111-134.

Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. / Hainsworth, Atticus H.; Stefani, Alessandro; Calabresi, Paolo; Smith, Terence W.; Leach, Michael J.

In: CNS Drug Reviews, Vol. 6, No. 2, 2000, p. 111-134.

Research output: Contribution to journalArticle

Hainsworth, AH, Stefani, A, Calabresi, P, Smith, TW & Leach, MJ 2000, 'Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor', CNS Drug Reviews, vol. 6, no. 2, pp. 111-134.
Hainsworth, Atticus H. ; Stefani, Alessandro ; Calabresi, Paolo ; Smith, Terence W. ; Leach, Michael J. / Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor. In: CNS Drug Reviews. 2000 ; Vol. 6, No. 2. pp. 111-134.
@article{2aa699d4e95b4a6088576b4ad2b57934,
title = "Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor",
abstract = "Sipatrigine is a substituted pyrimidine derived from lamotrigine. It attenuates glutamate release in vitro and in vivo, probably as a result of sodium and calcium channel inhibition. It consistently reduces cortical infarct volume in rodent models of global, permanent focal, and transient focal ischemia (typically 50-60{\%} reduction with maximum effective doses >20 mg/kg). Striatal protection was found in some studies but not others. The drug was effective also in a rat optic nerve model of white matter ischemia, providing complete neuroprotection at the highest concentration (100 μM) used. In monkeys, CNS penetration by sipatrigine was rapid and the steady state brain/plasma ratio was >40. In humans, low doses (<2 mg/kg, then 1 mg/kg/8 h) were well tolerated. At higher doses a significant incidence of hallucinations and vomiting was observed. These adverse effects were speculated to be due to interactions with muscarinic receptors and 5-HT3 (or sigma) receptors, respectively. Cardiovascular side effects appeared not to be a major concern. In electrophysiological studies, sipatrigine inhibited native neuronal sodium and calcium channels (including L, N, and P/Q type) and recombinant type IIA sodium and N and T type calcium channels, all with similar potency (IC50 in the range 5-16 μM). Inhibitory potency was increased by high action potential firing frequencies and a depolarized resting voltage. These properties may account for its actions in vitro and in animal models but do not exclude possible additional actions in later stages of ischemic damage.",
keywords = "Brain injury, Cerebral ischaemia, Excitotoxicity, Glutamate release, Lamotrigine, Neuroprotection, Sipatrigine, Stroke",
author = "Hainsworth, {Atticus H.} and Alessandro Stefani and Paolo Calabresi and Smith, {Terence W.} and Leach, {Michael J.}",
year = "2000",
language = "English",
volume = "6",
pages = "111--134",
journal = "CNS Drug Reviews",
issn = "1080-563X",
publisher = "Neva Press, Inc.",
number = "2",

}

TY - JOUR

T1 - Sipatrigine (BW 619C89) is a neuroprotective agent and a sodium channel and calcium channel inhibitor

AU - Hainsworth, Atticus H.

AU - Stefani, Alessandro

AU - Calabresi, Paolo

AU - Smith, Terence W.

AU - Leach, Michael J.

PY - 2000

Y1 - 2000

N2 - Sipatrigine is a substituted pyrimidine derived from lamotrigine. It attenuates glutamate release in vitro and in vivo, probably as a result of sodium and calcium channel inhibition. It consistently reduces cortical infarct volume in rodent models of global, permanent focal, and transient focal ischemia (typically 50-60% reduction with maximum effective doses >20 mg/kg). Striatal protection was found in some studies but not others. The drug was effective also in a rat optic nerve model of white matter ischemia, providing complete neuroprotection at the highest concentration (100 μM) used. In monkeys, CNS penetration by sipatrigine was rapid and the steady state brain/plasma ratio was >40. In humans, low doses (<2 mg/kg, then 1 mg/kg/8 h) were well tolerated. At higher doses a significant incidence of hallucinations and vomiting was observed. These adverse effects were speculated to be due to interactions with muscarinic receptors and 5-HT3 (or sigma) receptors, respectively. Cardiovascular side effects appeared not to be a major concern. In electrophysiological studies, sipatrigine inhibited native neuronal sodium and calcium channels (including L, N, and P/Q type) and recombinant type IIA sodium and N and T type calcium channels, all with similar potency (IC50 in the range 5-16 μM). Inhibitory potency was increased by high action potential firing frequencies and a depolarized resting voltage. These properties may account for its actions in vitro and in animal models but do not exclude possible additional actions in later stages of ischemic damage.

AB - Sipatrigine is a substituted pyrimidine derived from lamotrigine. It attenuates glutamate release in vitro and in vivo, probably as a result of sodium and calcium channel inhibition. It consistently reduces cortical infarct volume in rodent models of global, permanent focal, and transient focal ischemia (typically 50-60% reduction with maximum effective doses >20 mg/kg). Striatal protection was found in some studies but not others. The drug was effective also in a rat optic nerve model of white matter ischemia, providing complete neuroprotection at the highest concentration (100 μM) used. In monkeys, CNS penetration by sipatrigine was rapid and the steady state brain/plasma ratio was >40. In humans, low doses (<2 mg/kg, then 1 mg/kg/8 h) were well tolerated. At higher doses a significant incidence of hallucinations and vomiting was observed. These adverse effects were speculated to be due to interactions with muscarinic receptors and 5-HT3 (or sigma) receptors, respectively. Cardiovascular side effects appeared not to be a major concern. In electrophysiological studies, sipatrigine inhibited native neuronal sodium and calcium channels (including L, N, and P/Q type) and recombinant type IIA sodium and N and T type calcium channels, all with similar potency (IC50 in the range 5-16 μM). Inhibitory potency was increased by high action potential firing frequencies and a depolarized resting voltage. These properties may account for its actions in vitro and in animal models but do not exclude possible additional actions in later stages of ischemic damage.

KW - Brain injury

KW - Cerebral ischaemia

KW - Excitotoxicity

KW - Glutamate release

KW - Lamotrigine

KW - Neuroprotection

KW - Sipatrigine

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=0033847175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033847175&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 111

EP - 134

JO - CNS Drug Reviews

JF - CNS Drug Reviews

SN - 1080-563X

IS - 2

ER -